RightFit Trial Directory

Leukemia clinical trials in Salt Lake City, UT

27 recruiting leukemia studies with a site in Salt Lake City, UT.

All trials in Salt Lake City, UT · All Leukemia trials

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

American Fork, UT · Cedar City, UT · Logan, UT · +452 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Salt Lake City, UT · +174 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Salt Lake City, UT · +223 more sites

RecruitingPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Salt Lake City, UT · +134 more sites

RecruitingPhase 1 / Phase 2NCT04065399

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Sponsor: Syndax Pharmaceuticals

Salt Lake City, UT · +21 more sites

RecruitingPhase 2NCT07605416

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Sponsor: National Cancer Institute (NCI)

Salt Lake City, UT · +9 more sites

RecruitingPhase 1NCT05091424

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Sponsor: Hoffmann-La Roche

Salt Lake City, UT · +4 more sites

RecruitingPhase 2NCT07061951

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Sponsor: National Cancer Institute (NCI)

Salt Lake City, UT · +8 more sites

RecruitingPhase 2NCT06707493

Ivosidenib as Post-HSCT Maintenance for AML

Sponsor: Massachusetts General Hospital

Salt Lake City, UT · +6 more sites

RecruitingPhase 3NCT07277231

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Sponsor: BeOne Medicines

Salt Lake City, UT · +21 more sites

RecruitingPhase 1 / Phase 2NCT04925479

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Sponsor: Novartis Pharmaceuticals

Salt Lake City, UT · +7 more sites

RecruitingPhase 3NCT06852222

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Sponsor: Janssen Research & Development, LLC

Salt Lake City, UT · +58 more sites

RecruitingPhase 3NCT04293562

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Sponsor: Children's Oncology Group

Salt Lake City, UT · +185 more sites

RecruitingPhase 2NCT07221500

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Sponsor: Nurix Therapeutics, Inc.

Salt Lake City, UT · +26 more sites

RecruitingPhase 2NCT06824168

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Sponsor: Daiichi Sankyo

Salt Lake City, UT · +14 more sites

RecruitingPhase 2NCT04996875

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Sponsor: Cogent Biosciences, Inc.

Salt Lake City, UT · +13 more sites

RecruitingPhase 2 / Phase 3NCT03013998

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Sponsor: Beat AML, LLC

Salt Lake City, UT · +30 more sites

RecruitingPhase 1NCT06227026

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

Sponsor: University of Utah

Salt Lake City, UT

RecruitingPhase 1 / Phase 2NCT04726241

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Sponsor: PedAL BCU, LLC

Salt Lake City, UT · +163 more sites

RecruitingPhase 1NCT05131022

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Sponsor: Nurix Therapeutics, Inc.

Salt Lake City, UT · +17 more sites

RecruitingPhase 2NCT05405387

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

Sponsor: University of Utah

Salt Lake City, UT

RecruitingPhase 1 / Phase 2NCT05848687

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Sponsor: Tanja Andrea Gruber

Salt Lake City, UT · +16 more sites

RecruitingPhase 1NCT04771572

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Sponsor: Newave Pharmaceutical Inc

Salt Lake City, UT · +7 more sites

RecruitingPhase 1NCT05101551

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Sponsor: Norman J. Lacayo

Salt Lake City, UT · +8 more sites

RecruitingPhase 2NCT05183854

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

Sponsor: University of Utah

Salt Lake City, UT

RecruitingPhase 1 / Phase 2NCT04988555

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sponsor: Sumitomo Pharma America, Inc.

Salt Lake City, UT · +31 more sites

RecruitingPhase 1 / Phase 2NCT05643742

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Sponsor: CRISPR Therapeutics AG

Salt Lake City, UT · +3 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.